After a year of controversy and complaints, Sen. Elizabeth Warren is asking a federal watchdog to investigate GSK over its ...
Something seems to be going awry with GlaxoSmithKline's game plan for its respiratory franchise, with new products positioned ... increasing competition in the asthma and chronic obstructive ...
"Simultaneous regulatory submissions for two indications highlight our confidence in depemokimab to help reduce the burden of both asthma ... products. It is one of five key product launches that ...
In the US, asthma affects over ... National Medical (TASE:BLWV) Products Administration, following positive phase III trial results. These developments reflect GSK’s ongoing efforts to advance ...
The U.S. Food and Drug Administration (FDA) has accepted GlaxoSmithKlines (NYSE:GSK) biologics license application for ...
GSK's long-acting asthma drug halved attacks in phase 3, backing up blockbuster hopes “Today’s data build on the body of evidence supporting depemokimab as an ultra-long-acting treatment and ...
The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...
The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type ... Inflammation R&D, GSK. “Our SWIFT and ANCHOR ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback